Guj. Themis Biosyn
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
CTL Trusteeship, acting as debenture trustee, has disclosed that the entire promoter holding of Gujarat Themis Biosyn is now indirectly encumbered. Vividhmargi Investments, which owns 98.99% of promoter entity Pharmaceutical Business Group (India), has pledged 51% of PBGIL and given a non-disposal undertaking over another 47.99% to secure debentures issued by OSS Software Solutions Labs. PBGIL holds 47.02% of Gujarat Themis Biosyn, meaning the entire promoter stake is now indirectly tied to the third-party debt. The encumbrance was created on 29 June 2026 under a debenture trust deed dated 25 June 2026.
Powered by Tijori
CTL Trusteeship, acting as debenture trustee, has disclosed that the entire promoter holding of Gujarat Themis Biosyn is now indirectly encumbered. Vividhmargi Investments, which owns 98.99% of promoter entity Pharmaceutical Business Group (India), has pledged 51% of PBGIL and given a non-disposal undertaking over another 47.99% to secure debentures issued by OSS Software Solutions Labs. PBGIL holds 47.02% of Gujarat Themis Biosyn, meaning the entire promoter stake is now indirectly tied to the third-party debt. The encumbrance was created on 29 June 2026 under a debenture trust deed dated 25 June 2026.
Powered by Tijori
Gujarat Themis Biosyn has initiated arbitration proceedings against Optimus Drugs Private Limited, claiming over ₹90 crore for breach of a supply agreement. The company alleges Optimus Drugs terminated the contract in violation of agreed terms and failed to meet mandatory take-or-pay purchase obligations. It is seeking ₹75 crore as break fees, nearly ₹24 lakh in interest on delayed payments, and ₹15 crore in additional damages and financial losses. The arbitration is before a sole arbitrator. The company stated it does not expect any financial liability from penalties, as it is the claimant seeking recovery. No timeline for the arbitration was disclosed.
Powered by Tijori
Gujarat Themis Biosyn has initiated arbitration proceedings against Optimus Drugs Private Limited, claiming over ₹90 crore for breach of a supply agreement. The company alleges Optimus Drugs terminated the contract in violation of agreed terms and failed to meet mandatory take-or-pay purchase obligations. It is seeking ₹75 crore as break fees, nearly ₹24 lakh in interest on delayed payments, and ₹15 crore in additional damages and financial losses. The arbitration is before a sole arbitrator. The company stated it does not expect any financial liability from penalties, as it is the claimant seeking recovery. No timeline for the arbitration was disclosed.
Powered by Tijori
June 26 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
GUJARAT THEMIS BIOSYN - INITIATES ARBITRATION PROCEEDING AGAINST OPTIMUS DRUGS
GUJARAT THEMIS BIOSYN - CLAIMS OVER 902 MILLION RUPEES FROM OPTIMUS DRUGS
Source text: [ID:]
Further company coverage: GTHM.NS
(([email protected];))
June 26 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
GUJARAT THEMIS BIOSYN - INITIATES ARBITRATION PROCEEDING AGAINST OPTIMUS DRUGS
GUJARAT THEMIS BIOSYN - CLAIMS OVER 902 MILLION RUPEES FROM OPTIMUS DRUGS
Source text: [ID:]
Further company coverage: GTHM.NS
(([email protected];))
Gujarat Themis Biosyn's board has approved raising up to ₹1,000 crore through a qualified institutional placement, alongside a separate preferential issue to non-promoters whose terms are yet to be finalised. The fund-raising, equivalent to about a fifth of the company's market value, is intended to finance its recently announced ¥21.5 billion acquisition of Japanese CDMO MicroBiopharm Japan. The QIP will be conducted in one or more tranches subject to shareholder and regulatory approvals. The company did not specify the pricing or the number of shares to be issued.
Powered by Tijori
Gujarat Themis Biosyn's board has approved raising up to ₹1,000 crore through a qualified institutional placement, alongside a separate preferential issue to non-promoters whose terms are yet to be finalised. The fund-raising, equivalent to about a fifth of the company's market value, is intended to finance its recently announced ¥21.5 billion acquisition of Japanese CDMO MicroBiopharm Japan. The QIP will be conducted in one or more tranches subject to shareholder and regulatory approvals. The company did not specify the pricing or the number of shares to be issued.
Powered by Tijori
June 3 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
GUJARAT THEMIS BIOSYN - TO CONSIDER FUND RAISING PROPOSALS AT BOARD MEETING ON JUNE 6, 2026
Source text: ID:nBSE2pPqgj
Further company coverage: GTHM.NS
(([email protected];))
June 3 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
GUJARAT THEMIS BIOSYN - TO CONSIDER FUND RAISING PROPOSALS AT BOARD MEETING ON JUNE 6, 2026
Source text: ID:nBSE2pPqgj
Further company coverage: GTHM.NS
(([email protected];))
May 25 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
GUJARAT THEMIS BIOSYN LTD - APPROVES PROPOSAL FOR PREFERENTIAL ISSUE OF EQUITY SHARES TO NON-PROMOTERS
Source text: ID:nBSE7yzy2T
Further company coverage: GTHM.NS
(([email protected];))
May 25 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
GUJARAT THEMIS BIOSYN LTD - APPROVES PROPOSAL FOR PREFERENTIAL ISSUE OF EQUITY SHARES TO NON-PROMOTERS
Source text: ID:nBSE7yzy2T
Further company coverage: GTHM.NS
(([email protected];))
May 22 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
SIGNS DEFINITIVE AGREEMENT TO BUY MICROBIOPHARM JAPAN
DEAL CONSIDERATION ABOUT JPY 21.5 BILLION (13 BILLION RUPEES)
Source text: ID:nBSE7BLGbP
Further company coverage: GTHM.NS
(([email protected];;))
May 22 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
SIGNS DEFINITIVE AGREEMENT TO BUY MICROBIOPHARM JAPAN
DEAL CONSIDERATION ABOUT JPY 21.5 BILLION (13 BILLION RUPEES)
Source text: ID:nBSE7BLGbP
Further company coverage: GTHM.NS
(([email protected];;))
June 13 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
CEO TAPAS GUHA THAKURATA RESIGNS
SACHIN PATEL RE-DESIGNATED AS MANAGING DIRECTOR
Source text: ID:nBSE44dyYS
Further company coverage: GTHM.NS
(([email protected];))
June 13 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.NS:
CEO TAPAS GUHA THAKURATA RESIGNS
SACHIN PATEL RE-DESIGNATED AS MANAGING DIRECTOR
Source text: ID:nBSE44dyYS
Further company coverage: GTHM.NS
(([email protected];))
Feb 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
GUJARAT THEMIS BIOSYN LTD - APPOINTS BHAVIK SHAH AS CFO
Source text: ID:nBSE5q7g9f
Further company coverage: GTHM.BO
(([email protected];))
Feb 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
GUJARAT THEMIS BIOSYN LTD - APPOINTS BHAVIK SHAH AS CFO
Source text: ID:nBSE5q7g9f
Further company coverage: GTHM.BO
(([email protected];))
Oct 25 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
BHARAT DESAI TO RETIRE AS CFO EFFECTIVE 31 DECEMBER 2024
APPOINTS BHAVIK SHAH AS INTERIM CFO
Source text for Eikon: ID:nBSEK7y2t
Further company coverage: GTHM.BO
(([email protected];))
Oct 25 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
BHARAT DESAI TO RETIRE AS CFO EFFECTIVE 31 DECEMBER 2024
APPOINTS BHAVIK SHAH AS INTERIM CFO
Source text for Eikon: ID:nBSEK7y2t
Further company coverage: GTHM.BO
(([email protected];))
May 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
APPROVED ISSUE OF 1 BONUS SHARE FOR EVERY 2 SHARES
Source text for Eikon: ID:nBSE8JV51D
Further company coverage: GTHM.BO
(([email protected];))
May 14 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
APPROVED ISSUE OF 1 BONUS SHARE FOR EVERY 2 SHARES
Source text for Eikon: ID:nBSE8JV51D
Further company coverage: GTHM.BO
(([email protected];))
May 4 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
TO CONSIDER PROPOSAL OF SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE8BJnQy
Further company coverage: GTHM.BO
(([email protected];))
May 4 (Reuters) - Gujarat Themis Biosyn Ltd GTHM.BO:
TO CONSIDER PROPOSAL OF SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE8BJnQy
Further company coverage: GTHM.BO
(([email protected];))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Guj. Themis Biosyn do?
Gujarat Themis Biosyn Ltd. manufactures and markets bulk drugs and intermediates, specializing in anti-tuberculosis and antibiotic products. The company focuses on fermentation-based APIs and caters to domestic and international pharmaceutical markets.
Who are the competitors of Guj. Themis Biosyn?
Guj. Themis Biosyn major competitors are Concord Biotech, Medicamen Biotech, Unichem Laboratories, Gufic Biosciences, Novartis India, Zota Health Care, Panacea Biotec. Market Cap of Guj. Themis Biosyn is ₹4,050 Crs. While the median market cap of its peers are ₹3,995 Crs.
Is Guj. Themis Biosyn financially stable compared to its competitors?
Guj. Themis Biosyn seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Guj. Themis Biosyn pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Guj. Themis Biosyn latest dividend payout ratio is 14.97% and 3yr average dividend payout ratio is 13.59%
How has Guj. Themis Biosyn allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Guj. Themis Biosyn balance sheet?
Balance sheet of Guj. Themis Biosyn is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Guj. Themis Biosyn improving?
No, profit is decreasing. The profit of Guj. Themis Biosyn is ₹46.68 Crs for TTM, ₹48.77 Crs for Mar 2025 and ₹59.16 Crs for Mar 2024.
Is the debt of Guj. Themis Biosyn increasing or decreasing?
Yes, The net debt of Guj. Themis Biosyn is increasing. Latest net debt of Guj. Themis Biosyn is ₹154 Crs as of Mar-26. This is greater than Mar-25 when it was ₹4.8 Crs.
Is Guj. Themis Biosyn stock expensive?
Yes, Guj. Themis Biosyn is expensive. Latest PE of Guj. Themis Biosyn is 86.75, while 3 year average PE is 47.42. Also latest EV/EBITDA of Guj. Themis Biosyn is 55.66 while 3yr average is 34.06.
Has the share price of Guj. Themis Biosyn grown faster than its competition?
Guj. Themis Biosyn has given lower returns compared to its competitors. Guj. Themis Biosyn has grown at ~4.0% over the last 2yrs while peers have grown at a median rate of 9.26%
Is the promoter bullish about Guj. Themis Biosyn?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Guj. Themis Biosyn is 70.86% and last quarter promoter holding is 70.86%.
Are mutual funds buying/selling Guj. Themis Biosyn?
The mutual fund holding of Guj. Themis Biosyn is stable. The current mutual fund holding in Guj. Themis Biosyn is 1.16% while previous quarter holding is 1.16%.